Stay updated on our latest news and events.
Oral solid dosage (OSD) products remain the largest segment of the pharmaceutical market. Oral solids continue to be the most commonly used delivery vehicle to get drugs to patients. There are three main factors for this: they are cost-effective, relatively easy to manufacture, and most importantly, are patient friendly.
The COVID-19 pandemic has exposed several weaknesses in global pharmaceutical supply chains, this is particularly true when it comes to APIs. Governments have responded forcefully with production relocation initiatives encouraging manufacturers to source supplies from closer to home.
There are several novel approaches to improving bioavailability and solubility that have one commonality: they treat each molecule as unique.
Recipharm’s approach is to use conventional technologies whenever possible, as this will usually be more time- and cost-effective.
The last five to ten years have seen substantial changes across the pharmaceutical industry, many of which have had a significant impact on the dosage forms used for the administration of drugs.
All of these developments are translating into rapid evolution for the dosage forms we use to deliver drugs to patients.
As we have seen throughout the ongoing COVID-19 pandemic, genetic vaccines offer several advantages over traditional approaches. For a vaccine to be effective, the components of the disease of interest that provide protection from a disease (an antigen) must be incorporated or present in the candidate and induce a strong and appropriate immune response.
After completing her degree, Helene began her career at AstraZeneca as Quality Engineer before later becoming Associate Director of Materials Management. Helene worked her way up over her nine years to become Global Supply Director.
The rapid growth in biopharmaceuticals, an increasingly complex drug landscape, and the rising expectations from consumers around administration convenience, are all contributing factors driving demand for new delivery solutions across the pharma industry.
The pharma industry has faced unprecedented challenges since the outbreak of COVID-19. 2021 has the potential to provide a platform for change, as work and everyday life continues to be transformed as a result of the global pandemic and other key events in 2020.
Throughout the course of COVID-19, the market demand for fixed dose combinations (FDCs) used in treatment of fever and common colds has risen significantly. In response to this demand, a number of Recipharm’s customers have had to update their analytical methodologies to ensure they are workable throughout the lifecycle of the drug product.